Sign In
Buy SON
$48.50
-0.670 (-1.36%)
At Close: Jun 03, 2026
2 High-Yield Dividend Stocks to Buy With No Hesitation
03:06am, Tuesday, 28'th Oct 2025
Dividend stocks have historically outperformed non-dividend paying stocks. Sonoco Products has radically reshaped its business to focus on its core.
Mutual of America Capital Management LLC Cuts Stock Position in Sonoco Products Company $SON
04:16am, Sunday, 26'th Oct 2025
Mutual of America Capital Management LLC lessened its stake in Sonoco Products Company (NYSE: SON) by 3.0% during the undefined quarter, according to its most recent disclosure with the Securities and
Sonoco Products Company (SON) Q3 2025 Earnings Call Transcript
06:17pm, Thursday, 23'rd Oct 2025
Sonoco Products Company (NYSE:SON ) Q3 2025 Earnings Call October 23, 2025 8:00 AM EDT Company Participants Roger Schrum - Interim Head of Investor Relations Robert Coker - President, CEO & Director R
Sonoco Reports Third Quarter 2025 Results
05:23pm, Wednesday, 22'nd Oct 2025
HARTSVILLE, S.C., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Sonoco Products Company (“Sonoco” or the “Company”) (NYSE: SON), a global leader in high-value sustainable packaging, today reported financi
Yousif Capital Management LLC Sells 516 Shares of Sonoco Products Company $SON
04:42am, Monday, 20'th Oct 2025
Yousif Capital Management LLC lowered its stake in Sonoco Products Company (NYSE: SON) by 1.4% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The
Why Sonoco Products Stock May Continue To Underperform
01:43pm, Thursday, 16'th Oct 2025
Sonoco Products Company (NYSE:SON) is nearing the completion of its 18th and final phase in its Adhishthana cycle on the weekly charts. As the cycle approaches its conclusion, the stock's recent under
Daily Dividend Report: DUK, Realty Income, Cummins, Citizens, Sonoco
12:10pm, Wednesday, 15'th Oct 2025
Duke Energy today declared a quarterly cash dividend on its common stock of $1.065 per share. This dividend is payable on Dec. 16, 2025, to shareholders of record at the close of business on Nov. 14,
Evaluation of SON-1010 Using a Patient-Derived Tumoroid Platform to Support an Ongoing Phase 1 Study in Patients with Sarcoma
10:03am, Wednesday, 15'th Oct 2025
HOUSTON, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) is collaborating with Spanios on a non-clinical study using New Alternate Methodologies (NAM)-based patie
CORRECTION – Sonoco Declares Regular Quarterly Common Stock Dividend
04:45pm, Tuesday, 14'th Oct 2025
HARTSVILLE, S.C., Oct. 14, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Sonoco (NYSE: SON), please note that in the first paragraph of the release, the record
Sonoco Declares Regular Quarterly Common Stock Dividend
12:09pm, Tuesday, 14'th Oct 2025
HARTSVILLE, S.C., Oct. 14, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Sonoco (NYSE: SON) has declared a $0.53 per share quarterly common stock dividend.
51 September S&P Hi-Yield Aristocrats: 5 To Buy
07:08am, Friday, 26'th Sep 2025
The article highlights the top ten S&P Hi-Yield Aristocrats for September, with nine stocks offering attractive yields and fair pricing for dividend investors. Analyst forecasts project potential net
Sonoco to Reduce Debt and Boost Portfolio With ThermoSafe Divestment
11:01am, Tuesday, 09'th Sep 2025
SON strikes a $725 million deal to divest ThermoSafe, aiming to cut debt and sharpen focus on core packaging operations.
Sonoco to Sell ThermoSafe Business to Arsenal Capital Partners for Up to $725 Million
09:38am, Monday, 08'th Sep 2025
Sonoco Products struck a deal to sell its ThermoSafe temperature-assured packaging business to private-equity firm Arsenal Capital Partners for up to $725 million.
Sonoco Products: Worth The Patience Required
05:39am, Sunday, 31'st Aug 2025
Sonoco's transformation via M&A and debt reduction is progressing, but near-term results are weighed down by integration challenges and higher interest expenses. Organic growth and margin expansion ar
Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer
08:40am, Monday, 04'th Aug 2025
Sonnet's lead product, SON-1010 (IL12-F H AB), is being evaluated in combination with atezolizumab (Tecentriq ® ) in patients with advanced platinum-resistant ovarian cancer (PROC) (SB221)
